Tristel makes acquisition
Cambs-based sterilant manufacturer, Tristel plc, is to branch out beyond the hospital infection control market with the £1 million acquisition of Bolton’s Vernagene Ltd, a fellow chlorine dioxide specialist.
Tristel uses its proprietary chlorine dioxide chemistry to to fight hospital infections and superbugs such as MRSA while Vernagene focuses on the water treatment and food processing industries. The contracts that will divest Vernagene from the Verna Group have already been exchanged and it is anticipated the deal will be completed shortly.
The Tristel board believes Vernagene’s 200 customers, particularly the 40 UK hospitals it works with, will offer it significant cross-selling opportunities.
In the year ended March 31, 2006, Vernagene achieved sales of £1.18m (2005: £1.15m and 2004: £0.91m) and pre-tax profits of £301,000.
o Tristel has appointed Silk Pearce to strengthen its international product branding as the Cambridgeshire company continues to expand its portfolio of sterilisation products and moves increasingly into overseas markets.